Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

aTYR PHARMA (ATYR) Accumulated Depreciation & Amortization (2019 - 2025)

aTYR PHARMA's Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $4.8 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 6.3% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $4.8 million, up 6.3%, while the annual FY2025 figure was $4.8 million, 6.3% up from the prior year.
  • Accumulated Depreciation & Amortization reached $4.8 million in Q4 2025 per ATYR's latest filing, up from $4.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.4 million in Q4 2022 to a low of $4.5 million in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $5.3 million, with a median of $4.8 million recorded in 2025.
  • Peak YoY movement for Accumulated Depreciation & Amortization: dropped 27.27% in 2023, then increased 6.3% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $6.2 million in 2021, then grew by 3.2% to $6.4 million in 2022, then decreased by 27.27% to $4.6 million in 2023, then dropped by 1.71% to $4.5 million in 2024, then rose by 6.3% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Accumulated Depreciation & Amortization are $4.8 million (Q4 2025), $4.5 million (Q4 2024), and $4.6 million (Q4 2023).